Clin2
NCT07621237Likely a fitRecruiting

TNX-102 SL for Major Depressive Disorder

Major Depressive Episode (MDE)Major Depressive Disorder (MDD)Depression

Part of Mental health clinical trials.

This study tests whether a new medication called TNX-102 SL can reduce depression symptoms better than a placebo (inactive pill). You'll take the medication daily and have regular check-ins to see how you're doing.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
360 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have major depressive disorder (clinical depression) as your primary diagnosis
  • Your current depressive episode has lasted between 6 weeks and 18 months
  • You do not have psychotic features (such as hallucinations or delusions) or catatonic features (extreme lack of movement or response)
  • You have not failed 2 or more adequate trials of different antidepressant medications in the past
  • You have not used alcohol or other substances as a primary problem in the past 12 months
  • You are willing to stop most antidepressants for 4–6 weeks before starting the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07610473Recruiting· Phase 2
Testing DT-101 as an add-on for depression

This trial tests if a new medication, DT-101, can help when added to your current depression treatment. It's for adults with recurrent depression who may need extra support.

Phoenix, Arizona
NCT07226661Recruiting· Phase 2
Study of an investigational drug for depression

This trial tests an investigational medication for adults with major depressive disorder who are currently taking an antidepressant but still have symptoms. It aims to see if adding this new drug can improve mood better than a placebo.

Garden Grove, California
NCT07300969Recruiting· Phase 2
Testing DT-101 for adults with depression

This trial tests a new medicine called DT-101 to see if it helps people with depression. It is for adults who have had more than one depressive episode in their life.

Bentonville, Arkansas
NCT07772531Not yet recruiting· Phase 2
BMS-986511 for major depressive disorder

This study tests an investigational drug called BMS-986511 in adults with moderate to severe depression. The goal is to see if it can improve symptoms.

Phoenix, Arizona
NCT07785102Not yet recruiting· Early Phase 1
Ultra-accelerated TMS with NRX-101 for depression

This study tests a new approach for depression: a single day of ultra-accelerated transcranial magnetic stimulation (TMS) combined with one dose of an experimental drug called NRX-101. It aims to see if this combination can quickly improve mood in people with moderate to severe depression.

Belmont, Massachusetts
NCT06633016Recruiting· Phase 2
ABX-002 for major depression (add-on treatment)

This trial tests a new medication called ABX-002 as an add-on to your current antidepressant. It's for people with moderate to severe depression who haven't gotten enough help from their current antidepressant alone.

Birmingham, Alabama

Hear when a new Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.